based in bethlehem, pennsylvania, orasure technologies is a leader in the development, manufacture and distribution of oral fluid diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. these products include tests for the detection of antibodies to the hiv virus, including the oraquick® in-home hiv test, oraquick advance® rapid hiv-1/2 antibody test and the orasure® hiv-1 oral specimen collection device, a test for antibodies to the hcv virus, the oraquick® hcv rapid antibody test, and oral fluid testing solutions for drugs of abuse testing, including intercept® oral fluid drug testing system and q.e.d.® saliva alcohol test. orasure also manufactures and sells several leading cryosurgical products. these include: histofreezer®, a product for the cryosurgical removal of common and plantar warts and several other benign skin lesions, sold to the professional or physician office market, as well as an over-the-counter product fo
Company profile
Ticker
OSUR
Exchange
Website
CEO
Douglas Michels
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
364370966
OSUR stock data
Latest filings (excl ownership)
8-K
1.05
12 Apr 24
DEFA14A
Additional proxy soliciting materials
4 Apr 24
ARS
2023 FY
Annual report to shareholders
4 Apr 24
DEF 14A
Definitive proxy
3 Apr 24
PRE 14A
Preliminary proxy
22 Mar 24
10-K
2023 FY
Annual report
11 Mar 24
8-K
OraSure Reports Q4 ‘23 Revenue of $75.9 Million
27 Feb 24
8-K
Regulation FD Disclosure
4 Jan 24
8-K
Changes in Registrant's Certifying Accountant
5 Dec 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
Transcripts
OSUR
Earnings call transcript
2023 Q3
7 Nov 23
OSUR
Earnings call transcript
2023 Q2
3 Aug 23
OSUR
Earnings call transcript
2023 Q1
10 May 23
OSUR
Earnings call transcript
2022 Q4
14 Feb 23
OSUR
Earnings call transcript
2022 Q3
9 Nov 22
OSUR
Earnings call transcript
2022 Q2
10 Aug 22
OSUR
Earnings call transcript
2022 Q1
11 May 22
OSUR
Earnings call transcript
2021 Q4
24 Feb 22
OSUR
Earnings call transcript
2021 Q3
4 Nov 21
OSUR
Earnings call transcript
2021 Q2
4 Aug 21
Latest ownership filings
4
James A Datin
28 Mar 24
4
Kenneth J McGrath
5 Mar 24
4
Michele Marie Anthony
5 Mar 24
4
MANNER CARRIE EGLINTON
5 Mar 24
4
Kathleen Gallagher Weber
5 Mar 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G
DIMENSIONAL FUND ADVISORS LP
9 Feb 24
4
Kathleen Gallagher Weber
5 Feb 24
4
Michele Marie Anthony
5 Feb 24
SC 13G/A
BlackRock Inc.
22 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
96.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 211 |
Opened positions | 26 |
Closed positions | 18 |
Increased positions | 55 |
Reduced positions | 82 |
13F shares | Current |
---|---|
Total value | 392.08 bn |
Total shares | 73.96 mm |
Total puts | 4.20 k |
Total calls | 24.10 k |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 12.63 mm | $74.87 bn |
Vanguard | 5.40 mm | $32.00 bn |
Camber Capital Management | 4.25 mm | $25.21 bn |
Dimensional Fund Advisors | 3.61 mm | $21.38 bn |
Flynn James E | 3.47 mm | $63.01 mm |
Alger Associates | 3.41 mm | $39.80 mm |
Neuberger Berman | 3.13 mm | $18.60 bn |
STT State Street | 3.04 mm | $18.04 bn |
Cannell Capital | 2.82 mm | $16.73 bn |
American Capital Management | 1.82 mm | $10.79 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
26 Mar 24 | Datin James A | Common Stock | Payment of exercise | Dispose F | No | No | 6.2175 | 871 | 5.42 k | 87,510 |
26 Mar 24 | Datin James A | Common Stock | Grant | Acquire A | No | No | 6.2175 | 3,217 | 20.00 k | 88,381 |
1 Mar 24 | Kenneth J McGrath | Common Stock | Payment of exercise | Dispose F | No | No | 7.1925 | 5,616 | 40.39 k | 326,131 |
1 Mar 24 | Kenneth J McGrath | Common Stock | Grant | Acquire A | No | No | 0 | 58,759 | 0.00 | 331,747 |
1 Mar 24 | Michele Marie Miller | Common Stock | Payment of exercise | Dispose F | No | No | 7.1925 | 2,708 | 19.48 k | 101,954 |
1 Mar 24 | Michele Marie Miller | Common Stock | Grant | Acquire A | No | No | 0 | 24,336 | 0.00 | 104,662 |
1 Mar 24 | Eglinton Manner Carrie | Common Stock | Payment of exercise | Dispose F | No | No | 7.1925 | 29,647 | 213.24 k | 1,582,657 |
1 Mar 24 | Eglinton Manner Carrie | Common Stock | Grant | Acquire A | No | No | 0 | 260,688 | 0.00 | 1,612,304 |
1 Mar 24 | Kathleen Gallagher Weber | Common Stock | Payment of exercise | Dispose F | No | No | 7.1925 | 4,403 | 31.67 k | 296,892 |
1 Mar 24 | Kathleen Gallagher Weber | Common Stock | Grant | Acquire A | No | No | 0 | 41,171 | 0.00 | 301,295 |
News
Evercore ISI Group Maintains In-Line on OraSure Technologies, Lowers Price Target to $6.5
4 Apr 24
OraSure Technologies: Q4 Earnings Insights
27 Feb 24
OraSure Technologies Q4 2023 Adj EPS $0.22 Beats $0.09 Estimate, Sales $75.88M Beat $74.12M Estimate
27 Feb 24
Earnings Scheduled For February 27, 2024
27 Feb 24
Preview: OraSure Technologies's Earnings
26 Feb 24